EyePoint Pharmaceuticals, Inc

(NASDAQ:EYPT)

Latest On EyePoint Pharmaceuticals, Inc (EYPT):

Date/Time Type Description Signal Details
2023-05-30 14:28 ESTNewsEyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug SuccessN/A
2023-05-18 19:57 ESTNewsAlimera jumps 48% on deal with EyePoint for eye disorder therapy YutiqN/A
2023-05-04 11:48 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call TranscriptN/A
2023-05-03 23:29 ESTNewsEyePoint stock soars 20% after Q1 sees growth in Yutiq salesN/A
2023-05-03 10:09 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 beats by $0.13, revenue of $7.68M beats by $0.11MN/A
2023-05-02 22:14 ESTNewsEyePoint Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-02 16:14 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$1.16 misses by $0.54, revenue of $10.53M beats by $0.13MN/A
2023-03-02 16:13 ESTNewsEyePoint stock dips as Q4 net loss widens, revenue fallsN/A
2023-03-02 16:13 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 01:38 ESTNewsEyePoint Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-27 14:25 ESTNewsRallybio, EyePoint in collaboration for geographic atrophy therapyN/A
2023-01-23 14:54 ESTNewsEyePoint inks lease for setting up of new manufacturing facility in MassachusettsN/A
2023-01-04 19:07 ESTNewsEyePoint Pharmaceuticals promotes Jay S. Duker to PresidentN/A
2022-11-02 16:59 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.49 beats by $0.16, revenue of $10.01M misses by $0.91MN/A
2022-11-02 16:58 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call TranscriptN/A
2022-08-30 20:33 ESTNewsEyePoint Pharma stock tumbles 14% postmarket on subpoena related to Dexycu salesN/A
2022-08-30 04:14 ESTNewsEyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD SpaceN/A
2022-08-03 20:25 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74MN/A
2022-08-03 20:24 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call TranscriptN/A
2022-07-19 02:49 ESTNewsEyePoint reports preliminary Q2 net product revenue $11.3MN/A
2022-07-15 12:59 ESTNewsEyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMDN/A
2022-06-22 02:08 ESTNewsEyePoint, OcuMension's eye implant therapy implant Yutiq gets approval in ChinaN/A
2022-05-05 03:05 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.56 in-line, revenue of $9.3M misses by $0.59MN/A
2022-05-05 03:05 ESTNewsEyePoint Q1 net loss widens Y/Y; inks license deal with China's Betta for EYP-1901N/A
2022-05-05 03:04 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call TranscriptN/A
2022-05-03 13:09 ESTNewsEyePoint Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-09 23:17 ESTNewsEyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley BankN/A
2022-03-04 04:42 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-03 11:12 ESTNewsEyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75MN/A
2022-03-02 16:55 ESTNewsEyePoint Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-14 07:42 ESTNewsEyePoint Pharmaceuticals reports positive data EYP-1901 data for the treatment of wet AMDN/A
2021-12-08 06:00 ESTNewsEyePoint, ImprimisRx expand commercial alliance for Dexycu eye corticosteroidN/A
2021-11-20 08:20 ESTNewsEyepoint Pharmaceuticals (EYPT) Investor Presentation - SlideshowN/A
2021-11-17 17:02 ESTNewsEyePoint Pharma secures $100M capital raise via equity offeringN/A
2021-11-17 17:01 ESTNewsShares of EyePoint Pharma soar 27% after pricing $100M equity offeringN/A
2021-11-16 20:09 ESTNewsEyePoint Pharma slumps on offering of $100M common sharesN/A
2021-11-15 05:04 ESTNewsEyePoint Pharma reports positive EYP-1901 data for treatment of wet AMDN/A
2021-11-04 08:34 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 11:51 ESTNewsEyePoint Pharmaceuticals EPS misses by $0.18, misses on revenueN/A
2021-11-02 15:45 ESTNewsEyePoint Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-13 00:22 ESTNewsEyePoint says its wet AMD therapy posed no serious adverse events in early studyN/A
2021-08-05 04:20 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.09, beats on revenueN/A
2021-08-05 04:17 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 07:32 ESTNewsEyePoint Pharmaceuticals to join Russell 2000 and 3000 IndexN/A
2021-07-21 07:24 ESTNewsEyePoint Pharma reports positive EYP-1901 results in wet-AMDN/A
2021-05-05 15:43 ESTNewsEyePoint Pharmaceuticals EPS beats by $0.01, misses on revenueN/A
2021-05-05 15:39 ESTNewsEyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call TranscriptN/A
2021-04-23 12:43 ESTNewsEyePoint Pharmaceuticals End Of Year Earnings Call AnalysisN/A
2021-03-06 07:38 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 07:43 ESTEarnings EstimateAn EPS average of -$0.89 is estimated for the 2022 year.Buy

About EyePoint Pharmaceuticals, Inc (EYPT):

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Quotes by TradingView

See Advanced Chart

General

  • Name EyePoint Pharmaceuticals, Inc
  • Symbol EYPT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:10
  • Last Split Date2020-12-09
  • Fiscal Year EndDecember
  • IPO Date2005-01-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://eyepointpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.93
  • Price/Book (Most Recent Quarter) 16.32
  • Enterprise Value Revenue 8.65
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.71
  • Next Year EPS Estimate -$1.43
  • Next Quarter EPS Estimate -$0.62
  • Profit Margin -132%
  • Operating Margin -107%
  • Return on Assets -28%
  • Return on Equity -338%
  • Revenue 34.44 million
  • Earnings Per Share -$0.72
  • Revenue Per Share $2.68
  • Gross Profit 11.19 million
  • Quarterly Earnings Growth -17.4%
View More

Highlights

  • Market Capitalization 317.88 million
  • EBITDA -56213000
  • Analyst Target Price $19.25
  • Book Value Per Share $1.02
View More

Share Statistics

  • Shares Outstanding 28.74 million
  • Shares Float 19.88 million
  • % Held by Insiders 73%
  • % Held by Institutions 46.62%
  • Shares Short 381742
  • Shares Short Prior Month 350229
  • Short Ratio 0.8
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.33
  • 52 Week High $15.06
  • 52 Week Low $3.51
  • 50 Day Moving Average 12.02
  • 200 Day Moving Average 7.3
View More

Dividends

  • Dividend Date 2020-12-09
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

EyePoint Pharmaceuticals, Inc (EYPT) Dividend Calendar:

EYPT's last dividend payment was made to shareholders on December 9, 2020.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

EyePoint Pharmaceuticals, Inc (EYPT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$7.13 million-$1.07-$0.17-536.9%
2020-09-302020-11-05$N/A-$0.30-$0.3718.19%
2020-06-302020-08-05$N/A-$1.00-$1.109.09%
2020-03-312020-05-06$7.49 million-$1.10-$0.97-13.79%
2019-12-312020-03-05$8.63 million-$1.00-$1.1513.04%
2019-09-302019-11-07$2.51 million-$1.50-$1.25-20%
2019-06-302019-08-07$7.21 million-$1.10-$1.4021.43%
2019-03-312019-05-08$2.01 million-$2.00-$0.90-122.22%
2018-12-312019-03-14$2.44 million-$1.20-$1.4014.29%
2018-09-302018-11-06$486000-$0.44-$0.15-193.33%
2018-06-302018-09-12$715000-$6.20-$1.07-481.23%
2018-03-312018-05-08$928000-$1.50-$1.30-15.38%
2017-12-312018-02-07$933000-$1.30-$1.5013.33%
2017-09-302017-11-07$385000-$1.50-$1.500%
2017-06-302017-09-11$701000-$1.60-$1.50-6.67%
2017-03-312017-05-04$590000-$1.50-$1.500%
2016-12-312017-02-07$5.97 million$-0.00-$1.8399.89%
2016-09-302016-11-07$277000-$2.10-$1.90-10.53%
2016-06-302016-09-12$304000-$1.90-$1.25-52%
2016-03-312016-05-05$324000-$1.50-$1.9523.08%
2015-12-312016-02-08$526000-$1.80-$1.50-20%
2015-09-302015-11-05$466000-$0.17-$0.14-21.43%
2015-06-302015-09-09$409000-$0.17-$0.13-30.77%
2015-03-312015-05-08$328000-$0.17-$0.13-30.77%
2014-12-312015-02-05$521000-$0.14-$0.13-7.69%
2014-09-302014-11-07$25.31 million$0.67-$0.12658.33%
2014-06-302014-09-09$292000-$0.14-$0.140%
2014-03-312014-05-13$1.99 million-$0.08-$0.1546.67%
2013-12-312014-02-07$592000-$0.13-$0.130%
2013-09-302013-11-12$597000-$0.14-$0.13-7.69%
2013-06-302013-09-25$492000-$0.17-$0.12-41.67%
2013-03-312013-05-13$513000-$0.12-$0.137.69%
2012-12-312013-02-06$585000-$0.11-$0.1315.38%
2012-09-302012-11-08$553000-$0.11-$0.10-10%
2012-06-302012-09-24$699000-$0.11-$0.1942.11%
2012-03-312012-05-09$538000-$0.13-$0.1723.53%
2011-12-312012-02-08$630000-$0.13-$0.1723.53%
2011-09-302011-11-07$1.66 million-$0.12-$0.2142.86%
2011-06-302011-09-12$3.72 million-$0.01-$0.1894.44%
2011-03-312011-05-10$360000-$0.13-$0.2138.1%
2010-12-312011-02-09$414000-$0.15$0.45-133.33%
2010-09-302010-11-05$476000-$0.17-$0.14-21.43%
2010-06-302010-09-23$15.72 million$6.80
2010-03-312010-05-12$515000-$0.15-$0.1922.95%
2009-12-312010-02-12$3.43 million-$0.01
2009-09-302009-11-13$3.38 million-$0.87
2009-06-302009-09-25$3.22 million-$0.29
2009-03-312009-05-13$3.16 million-$0.35
2008-12-312009-02-11$2.97 million-$0.48
2008-09-302008-11-11$2.81 million-$0.26
2008-06-302008-06-30$2.7 million-$35.00
2008-03-312008-03-31$542000-$12.05
2007-12-312007-12-31$128000-$12.70
2007-09-302007-09-30$103000-$1.78

EyePoint Pharmaceuticals, Inc (EYPT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

EyePoint Pharmaceuticals, Inc (EYPT) Chart:

EyePoint Pharmaceuticals, Inc (EYPT) News:

Below you will find a list of latest news for EyePoint Pharmaceuticals, Inc (EYPT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

EyePoint Pharmaceuticals, Inc (EYPT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-05-162.50CALL0 0393.7TRUE00
2025-05-1651.6CALL1 981.9TRUE-0.2-0.11
2025-05-167.50.15CALL1 14370.23FALSE-0.14-0.48
2025-05-16100.05CALL0 6107.8FALSE00
2025-05-1612.50CALL0 0243.53FALSE00
2025-05-162.50PUT0 0426.11FALSE00
2025-05-1650PUT0 0130.16FALSE00
2025-05-167.51.1PUT5 271.43TRUE1.10
2025-05-16100PUT0 0207.48TRUE00
2025-05-1612.50PUT0 0261.9TRUE00
2025-06-202.50CALL0 0211.22TRUE00
2025-06-2050CALL0 077.82TRUE00
2025-06-207.50.75CALL0 882.85FALSE00
2025-06-20100CALL0 0105.51FALSE00
2025-06-202.50PUT0 0265.61FALSE00
2025-06-2050.46PUT0 1114.58FALSE00
2025-06-207.50PUT0 083.73TRUE00
2025-06-20100PUT0 073.62TRUE00
2025-07-182.56.4CALL0 2197.16TRUE00
2025-07-1851.52CALL0 9695.73TRUE00
2025-07-187.50.55CALL0 15177.37FALSE00
2025-07-18100.3CALL0 28386FALSE00
2025-07-1812.50.34CALL0 96123.05FALSE00
2025-07-18150CALL0 0142.94FALSE00
2025-07-1817.50CALL0 0158.75FALSE00
2025-07-18200.15CALL0 293128.36FALSE00
2025-07-1822.50CALL0 0183FALSE00
2025-07-182.50PUT0 0218.09FALSE00
2025-07-1851.5PUT0 75110.93FALSE00
2025-07-187.51.45PUT0 12881.82TRUE00
2025-07-18103.43PUT0 2090.02TRUE00
2025-07-1812.54.7PUT0 0157.46TRUE00
2025-07-18150PUT0 0184.58TRUE00
2025-07-1817.50PUT0 0207.37TRUE00
2025-07-18200PUT0 0187.83TRUE00
2025-07-1822.50PUT0 0182.11TRUE00
2025-10-172.54.59CALL3 5142.3TRUE0.160.04
2025-10-1750CALL0 0103.62TRUE00
2025-10-177.51.2CALL0 31578.69FALSE00
2025-10-17100.3CALL0 5580.39FALSE00
2025-10-1712.50.33CALL0 10078.86FALSE00
2025-10-17150CALL0 098.54FALSE00
2025-10-172.50.12PUT0 1152.87FALSE00
2025-10-1750.8PUT0 2982.27FALSE00
2025-10-177.52.7PUT0 11180.03TRUE00
2025-10-17100PUT0 066.56TRUE00
2025-10-1712.50PUT0 078.26TRUE00
2025-10-17150PUT0 0130.67TRUE00
2026-01-162.54.11CALL0 0120.05TRUE00
2026-01-1652.3CALL0 14084.12TRUE00
2026-01-167.51.5CALL5 17279.82FALSE1.50
2026-01-16100.9CALL0 48576.44FALSE00
2026-01-1612.50.35CALL0 33277.97FALSE00
2026-01-16150.4CALL4 55880.99FALSE00
2026-01-1617.50.1CALL0 27383.21FALSE00
2026-01-16200.54CALL0 21103.85FALSE00
2026-01-1622.50.25CALL0 54111.89FALSE00
2026-01-16250.35CALL0 157105.85FALSE00
2026-01-16300.05CALL0 16789.97FALSE00
2026-01-16350.15CALL0 306109.12FALSE00
2026-01-16400.15CALL0 25233.07FALSE00
2026-01-16450.18CALL0 7136.07FALSE00
2026-01-162.50.25PUT0 887.82FALSE00
2026-01-1651.1PUT0 75758.48FALSE00
2026-01-167.53.9PUT0 45279.15TRUE00
2026-01-16105.7PUT0 62977.34TRUE00
2026-01-1612.56.56PUT0 22879.94TRUE00
2026-01-16158.1PUT0 199.24TRUE00
2026-01-1617.511.41PUT0 194.53TRUE00
2026-01-16209PUT0 0103.7TRUE00
2026-01-1622.50PUT0 0115.5TRUE00
2026-01-162515.5PUT0 0122.7TRUE00
2026-01-16300PUT0 0135.16TRUE00
2026-01-16350PUT0 0162.15TRUE00
2026-01-16400PUT0 0261.68TRUE00
2026-01-16450PUT0 0193.79TRUE00

Latest EYPT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST10$7.555
Jun 13, 2022 7:59 PM EST4$7.555
Jun 13, 2022 7:59 PM EST32$7.555
Jun 13, 2022 7:59 PM EST5$7.53
Jun 13, 2022 7:59 PM EST100$7.53

EyePoint Pharmaceuticals, Inc (EYPT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2018-11-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314102/000000000018036896/0000000000-18-036896-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2018-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm
2019-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000089924319003415/0000899243-19-003415-index.htm
2018-10-31S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518314121/0001193125-18-314121-index.htm
2018-11-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518315426/0001193125-18-315426-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312518318982/0001193125-18-318982-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312518323795/0001193125-18-323795-index.htm
2018-11-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314102/000119312518336713/0001193125-18-336713-index.htm
2018-12-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314102/000119312518345921/0001193125-18-345921-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519002516/0001193125-19-002516-index.htm
2019-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519008307/0001193125-19-008307-index.htm
2019-01-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519012973/0001193125-19-012973-index.htm
2019-01-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519012979/0001193125-19-012979-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519020750/0001193125-19-020750-index.htm
2019-02-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1314102/000119312519037699/0001193125-19-037699-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519044197/0001193125-19-044197-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519073987/0001193125-19-073987-index.htm
2019-03-1810-KTTransition reports [Rule 13a-10 or 15d-10]https://www.sec.gov/Archives/edgar/data/1314102/000119312519078454/0001193125-19-078454-index.htm
2019-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519088540/0001193125-19-088540-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519092951/0001193125-19-092951-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519094684/0001193125-19-094684-index.htm
2019-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519121055/0001193125-19-121055-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125776/0001193125-19-125776-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000119312519125782/0001193125-19-125782-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519140432/0001193125-19-140432-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000119312519144237/0001193125-19-144237-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519153328/0001193125-19-153328-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/0001193125-19-185970-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519192395/0001193125-19-192395-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519195624/0001193125-19-195624-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312519214582/0001193125-19-214582-index.htm
2019-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312519216909/0001193125-19-216909-index.htm
2020-02-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520043553/0001193125-20-043553-index.htm
2020-02-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520046322/0001193125-20-046322-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314102/000119312520210092/0001193125-20-210092-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000119312520217649/0001193125-20-217649-index.htm
2020-11-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314102/000119312520287418/0001193125-20-287418-index.htm
2019-01-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000562/0001562180-19-000562-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019000563/0001562180-19-000563-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002006/0001562180-19-002006-index.htm
2019-03-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002007/0001562180-19-002007-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2019-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2019-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2019-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003506/0001562180-19-003506-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003509/0001562180-19-003509-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003660/0001562180-19-003660-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003661/0001562180-19-003661-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003662/0001562180-19-003662-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003663/0001562180-19-003663-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003664/0001562180-19-003664-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003665/0001562180-19-003665-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003666/0001562180-19-003666-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003667/0001562180-19-003667-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003668/0001562180-19-003668-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003669/0001562180-19-003669-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2019-06-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003958/0001562180-19-003958-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019003959/0001562180-19-003959-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005159/0001562180-19-005159-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005160/0001562180-19-005160-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005547/0001562180-19-005547-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002036/0001562180-20-002036-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002042/0001562180-20-002042-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002043/0001562180-20-002043-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002044/0001562180-20-002044-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002045/0001562180-20-002045-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002046/0001562180-20-002046-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002047/0001562180-20-002047-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002048/0001562180-20-002048-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002049/0001562180-20-002049-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002050/0001562180-20-002050-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002051/0001562180-20-002051-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002054/0001562180-20-002054-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2020-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019029987/0001564590-19-029987-index.htm
2019-08-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019032836/0001564590-19-032836-index.htm
2019-09-098-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019034357/0001564590-19-034357-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019041352/0001564590-19-041352-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459019041819/0001564590-19-041819-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019043812/0001564590-19-043812-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044172/0001564590-19-044172-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459019044762/0001564590-19-044762-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020000993/0001564590-20-000993-index.htm
2020-01-168-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001223/0001564590-20-001223-index.htm
2020-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020001745/0001564590-20-001745-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020003097/0001564590-20-003097-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020005550/0001564590-20-005550-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020006023/0001564590-20-006023-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020008797/0001564590-20-008797-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314102/000156459020010956/0001564590-20-010956-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020015451/0001564590-20-015451-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020017306/0001564590-20-017306-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019026/0001564590-20-019026-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019028/0001564590-20-019028-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020019253/0001564590-20-019253-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020021535/0001564590-20-021535-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020023640/0001564590-20-023640-index.htm
2020-06-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020028332/0001564590-20-028332-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020029661/0001564590-20-029661-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020030273/0001564590-20-030273-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020032264/0001564590-20-032264-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036425/0001564590-20-036425-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020036429/0001564590-20-036429-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020036461/0001564590-20-036461-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020037729/0001564590-20-037729-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020040715/0001564590-20-040715-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020043596/0001564590-20-043596-index.htm
2020-10-06PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045941/0001564590-20-045941-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020045966/0001564590-20-045966-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046049/0001564590-20-046049-index.htm
2020-10-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046585/0001564590-20-046585-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046623/0001564590-20-046623-index.htm
2020-10-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314102/000156459020046655/0001564590-20-046655-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314102/000156459020050850/0001564590-20-050850-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314102/000156459020051654/0001564590-20-051654-index.htm
2018-11-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518002780/9999999995-18-002780-index.htm
2018-12-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314102/999999999518003103/9999999995-18-003103-index.htm

EyePoint Pharmaceuticals, Inc (EYPT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyePoint Pharmaceuticals, Inc (EYPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 73%
Institutional Ownership: 4662%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-15George ElstonChief Financial OfficerBuy10,000.001.4314,290.0010,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005548/0001562180-19-005548-index.htm
2020-06-30Dario A. PaggiarinoChief Medical OfficerBuy41,050.00101,193.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004869/0001562180-20-004869-index.htm
2018-11-15MICHAEL W ROGERSDirectorBuy100,000.001.13113,000.00112,500.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318029124/0000899243-18-029124-index.htm
2019-06-21MICHAEL W ROGERSDirectorBuy6,667.00119,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003630/0001562180-19-003630-index.htm
2019-03-29David J MazzoDirectorBuy20,000.001.7735,400.00158,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002054/0001562180-19-002054-index.htm
2019-06-21David J MazzoDirectorBuy8,333.00166,333.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003629/0001562180-19-003629-index.htm
2019-09-06David J MazzoDirectorBuy417.00166,750.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019004701/0001562180-19-004701-index.htm
2019-04-01Jay S. DukerDirectorBuy5,000.001.899,450.0017,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002168/0001562180-19-002168-index.htm
2020-03-12George ElstonChief Financial OfficerBuy10,000.000.969,600.0020,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002451/0001562180-20-002451-index.htm
2019-10-09David J MazzoDirectorBuy33,333.001.9564,999.35200,083.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019005150/0001562180-19-005150-index.htm
2019-03-29Nancy LurkerPresident & CEOBuy28,500.001.7650,245.50240,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002055/0001562180-19-002055-index.htm
2019-06-14Nancy LurkerPresident & CEOBuy45,000.00285,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003562/0001562180-19-003562-index.htm
2019-03-29Douglas Evan GodshallDirectorBuy17,000.001.7529,784.0029,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002053/0001562180-19-002053-index.htm
2020-08-24George ElstonChief Financial OfficerBuy10,000.000.616,112.0030,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005659/0001562180-20-005659-index.htm
2019-06-27Nancy LurkerPresident & CEOBuy40,000.00325,200.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003675/0001562180-19-003675-index.htm
2019-06-21Douglas Evan GodshallDirectorBuy6,667.0036,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003627/0001562180-19-003627-index.htm
2019-04-12Jay S. DukerDirectorBuy20,000.001.7735,400.0037,500.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002284/0001562180-19-002284-index.htm
2020-09-04George ElstonChief Financial OfficerBuy10,000.000.484,800.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020005930/0001562180-20-005930-index.htm
2019-05-13John B. LandisDirectorBuy40,000.001.7469,600.0040,000.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002822/0001562180-19-002822-index.htm
2020-06-30David Scott JonesSVP & Chief Commercial OfficerBuy41,050.0041,050.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004870/0001562180-20-004870-index.htm
2019-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0042,612.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003560/0001562180-19-003560-index.htm
2019-06-21Jay S. DukerDirectorBuy6,667.0044,167.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003626/0001562180-19-003626-index.htm
2020-02-21Nancy LurkerPresident & CEOBuy137,174.00476,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020001682/0001562180-20-001682-index.htm
2019-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0048,437.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003676/0001562180-19-003676-index.htm
2020-06-14Dario A. PaggiarinoChief Medical OfficerBuy14,200.0057,247.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004516/0001562180-20-004516-index.htm
2020-03-10Nancy LurkerPresident & CEOBuy98,000.001.06104,027.00574,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020002379/0001562180-20-002379-index.htm
2020-06-14Nancy LurkerPresident & CEOBuy45,000.00619,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004517/0001562180-20-004517-index.htm
2020-06-27Dario A. PaggiarinoChief Medical OfficerBuy10,000.0063,079.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004723/0001562180-20-004723-index.htm
2020-06-27Nancy LurkerPresident & CEOBuy40,000.00659,800.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004716/0001562180-20-004716-index.htm
2019-06-21Kristine PetersonDirectorBuy6,667.006,667.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003628/0001562180-19-003628-index.htm
2020-06-30Nancy LurkerPresident & CEOBuy124,667.00784,467.00https://www.sec.gov/Archives/edgar/data/1314102/000156218020004867/0001562180-20-004867-index.htm
2019-04-01Leonard S RossOfficerBuy5,000.001.819,050.0079,452.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019002080/0001562180-19-002080-index.htm
2019-06-14Leonard S RossOfficerBuy8,280.0087,732.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003561/0001562180-19-003561-index.htm
2019-06-27Leonard S RossOfficerBuy6,667.0092,005.00https://www.sec.gov/Archives/edgar/data/1314102/000156218019003677/0001562180-19-003677-index.htm
2018-12-22Leonard S RossOfficerBuy62,892.0094,709.00https://www.sec.gov/Archives/edgar/data/1314102/000089924318031698/0000899243-18-031698-index.htm